Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.22.1
Commitments and Contingencies (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Sep. 30, 2021
USD ($)
payment
Feb. 03, 2020
USD ($)
milestone
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
therapy
milestone
Aug. 31, 2017
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Aug. 31, 2019
USD ($)
Operating Leased Assets [Line Items]                              
Maximum potential future payments $ 3,000                            
General and administrative expense           $ 9,756 $ 4,911                
Payment received     $ 2,000                        
Period after public launch to terminate agreement     3 years                        
Percentage of net present value of royalty payments     75.00%                        
Aevi                              
Operating Leased Assets [Line Items]                              
Milestone payment           0                  
AYTU | Deerfield Obligation                              
Operating Leased Assets [Line Items]                              
Maximum potential future payments $ 3,000                            
Number of quarterly payments | payment 6                            
Periodic payment $ 500                            
Aevi                              
Operating Leased Assets [Line Items]                              
Number of milestones | milestone   2                          
Contingent consideration   $ 6,500                          
Ichorion                              
Operating Leased Assets [Line Items]                              
Number of milestones | milestone       3                      
Contingent consideration       $ 15,000                      
Milestone payment           0                  
AVTX-801, AVTX-802, And AVTX-803 | Ichorion                              
Operating Leased Assets [Line Items]                              
Number of preclinical therapies | therapy       3                      
AVTX-913 | Ichorion                              
Operating Leased Assets [Line Items]                              
Number of preclinical therapies | therapy       1                      
Milestone One | Aevi                              
Operating Leased Assets [Line Items]                              
Contingent consideration   2,000                          
Milestone One | Ichorion                              
Operating Leased Assets [Line Items]                              
Milestone payment                 $ 6,000            
Milestone Two | Aevi                              
Operating Leased Assets [Line Items]                              
Contingent consideration   $ 4,500                          
Milestone Two | Ichorion | Forecast                              
Operating Leased Assets [Line Items]                              
Milestone payment                   $ 5,000          
Milestone Three | Ichorion                              
Operating Leased Assets [Line Items]                              
Milestone payment           0                  
Milestone Three | Ichorion | Forecast                              
Operating Leased Assets [Line Items]                              
Milestone payment                   $ 4,000          
Alto | AVTX-301 Out-License                              
Operating Leased Assets [Line Items]                              
Maximum proceeds from milestones                         $ 18,600    
Revenue recognized from milestones to date           0                  
ES | AVTX-406 License Assignment                              
Operating Leased Assets [Line Items]                              
Revenue recognized from milestones to date           0                  
ES | AVTX-611 License Assignment                              
Operating Leased Assets [Line Items]                              
Maximum proceeds from milestones                             $ 20,000
Revenue recognized from milestones to date           0                  
ES | Milestone One | AVTX-406 License Assignment                              
Operating Leased Assets [Line Items]                              
Maximum proceeds from milestones                       $ 6,000      
ES | Milestone Two | AVTX-406 License Assignment                              
Operating Leased Assets [Line Items]                              
Maximum proceeds from milestones                       $ 20,000      
Janssen Pharmaceuticals, Inc. (Janssen) | AVTX-501                              
Operating Leased Assets [Line Items]                              
Maximum proceeds from milestones         $ 20,000                    
Revenue recognized from milestones to date           0                  
Proceeds from sale         $ 25,000                    
Karbinal Agreement | TRIS Pharma                              
Operating Leased Assets [Line Items]                              
Minimum quantity required | unit               70,000              
Make whole payment per unit (in dollars per share) | $ / shares               $ 30              
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC)                              
Operating Leased Assets [Line Items]                              
Upfront license fee                           $ 10,000  
Percent of payments received from sublicensing                           30.00%  
Research and development expense           0 10,000                
Cumulative expense recognized to date           0                  
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone One                              
Operating Leased Assets [Line Items]                              
Maximum aggregate milestone payment                           $ 112,500  
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone Two                              
Operating Leased Assets [Line Items]                              
Maximum aggregate milestone payment                           $ 75,000  
AVTX-006 Astellas License Agreement | Astellas Pharma, Inc. (Astellas)                              
Operating Leased Assets [Line Items]                              
Upfront license fee           500                  
Maximum aggregate milestone payment           5,500                  
Research and development expense           0                  
Cumulative expense recognized to date           500                  
AVTX-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca)                              
Operating Leased Assets [Line Items]                              
Upfront license fee           6,000                  
Research and development expense           0                  
Cumulative expense recognized to date           1,500                  
AVTX-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca) | Milestone One                              
Operating Leased Assets [Line Items]                              
Maximum aggregate milestone payment           71,500                  
AVTX-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca) | Milestone Two                              
Operating Leased Assets [Line Items]                              
Maximum aggregate milestone payment           90,000                  
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute                              
Operating Leased Assets [Line Items]                              
Upfront license fee                     $ 400        
Research and development expense           0 $ 400                
Cumulative expense recognized to date           0                  
Patent costs                     500        
General and administrative expense           $ 500                  
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone One                              
Operating Leased Assets [Line Items]                              
Maximum aggregate milestone payment                     24,200        
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone Two                              
Operating Leased Assets [Line Items]                              
Maximum aggregate milestone payment                     $ 50,000